CONCLUSIONS — Exenatide signiﬁcantly reduced A1C in patients with type 2 diabetes unable to achieve adequate glycemic control with maximally effective doses of combined metformin-sulfonylurea therapy. This improvement in glycemic control was associated with noweight gain and was generally well tolerated. Diabetes Care 28:1083–1091, 2005In most individuals with type 2 diabe- tes, hyperglycemia results from a fail- ure of/H9252-cell insulin secretory capacity to adequately compensate for insulin re-sistance in peripheral tissues (1,2). Re-sults from the U.K. Prospective DiabetesStudy indicate that /H9252-cell failure is a pro-